FibroGen vs. Hangzhou Andao: Indolizine Patent Dispute Dismissed With Prejudice
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | FibroGen, Inc. v. Hangzhou Andao Pharmaceutical, Ltd. et al. |
| Numéro de dossier | 3:22-cv-07148 (N.D. Cal.) |
| Tribunal | Tribunal fédéral de première instance pour le district nord de Californie |
| Durée | Nov 2022 – Apr 2024 515 days |
| Résultat | Defendant Win — Dismissed with Prejudice |
| Brevets en cause | |
| Produits incriminés | Indolizine Derivatives & Medical Applications |
Aperçu du dossier
Les parties
⚖️ Demandeur
A San Francisco-based biopharmaceutical company known for its work in fibrosis and anemia therapeutics, maintaining a substantial patent portfolio in small-molecule chemistry.
🛡️ Défendeur
A China-based pharmaceutical developer, along with co-defendants Kind Pharmaceuticals, LLC, Dr. Dong Liu, and Dr. Shaojiang Deng, suggesting allegations tied to research personnel or parallel commercialization efforts.
Le brevet en cause
This litigation centered on **U.S. Patent No. US11021478B2** (Application No. US16/611838), directed to indolizine derivatives and their application in medicine. Indolizine-based compounds are a significant area of pharmaceutical innovation, with applications in oncology, inflammation, and other therapeutic categories.
- • US11021478B2 — Indolizine derivatives and medical applications
Developing novel chemical compounds?
Check if your small-molecule structures might infringe existing patents before synthesis or trials.
Le verdict et l'analyse juridique
Résultat
On **April 12, 2024**, the court entered an order pursuant to a **Joint Stipulation of Dismissal**, with all claims by FibroGen, Inc. and all counterclaims by the defendants dismissed **with prejudice**. Each party was ordered to bear its own fees and costs. This outcome signals a negotiated resolution, preventing FibroGen from re-filing the same claims against these defendants.
Principales questions juridiques
The absence of a public damages award or disclosed settlement amount is consistent with confidential resolution terms. While specific procedural milestones are not detailed, the 515-day litigation arc and the decision to dismiss with prejudice suggest the parties reached a mutual, bilateral resolution. Pharmaceutical patent infringement cases often turn on complex claim construction, validity challenges based on prior art, or inventorship disputes, especially when individual scientists are named as defendants, as in this case.
Freedom to Operate (FTO) Analysis for Indolizine Derivatives
This case highlights critical IP risks in small-molecule drug development. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- View related patent families in this technology space
- See which companies are most active in indolizine IP
- Understand chemical claim construction patterns
🔍 Vérifier les risques liés à mon produit
Run a comprehensive FTO analysis for your own chemical compounds or therapeutic products.
- Input your chemical structures or technical features
- L'IA identifie les brevets susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
Indolizine scaffolds in therapeutics
Key Patent Family
US11021478B2
FTO proactif essentiel
Before chemical synthesis and clinical trials
✅ Points clés à retenir
Bilateral dismissal with prejudice and mutual cost-bearing strongly suggests a confidential settlement.
Rechercher la jurisprudence connexe →Naming individual scientist-defendants remains a viable pressure tactic in pharmaceutical patent cases, potentially expanding trade secret or inventorship angles.
Explorer les stratégies contentieuses →Foire aux questions
The case involved U.S. Patent No. US11021478B2 (Application No. US16/611838), directed to indolizine derivatives and their application in medicine.
The court entered dismissal pursuant to a Joint Stipulation filed by all parties, consistent with a negotiated resolution. Dismissal with prejudice prevents FibroGen from re-asserting the same claims against these defendants.
The patent remains valid and unadjudicated on the merits, preserving FibroGen’s ability to assert it against other parties. Companies developing indolizine-based therapeutics should conduct targeted FTO reviews against this patent family.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- PACER Case Locator – Case 3:22-cv-07148
- USPTO Patent Center – US11021478B2
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.